Par Drugs Peer Comparison

NSE: PAR

₹114.96

₹5.47 (5.00%)

As on 28-Oct-2026 12:02IST

Market cap

₹141 Cr

Revenue (TTM)

₹109 Cr

P/E Ratio

9.8

P/B Ratio

1.2

Div. Yield

0 %

Edit

	Par Drugs	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Market cap (₹ Cr)	141	30,962	31,194	30,308	25,735
Revenue (₹ Cr)	109	3,564	1,593	5,155	1,936
Net Profit (₹ Cr)	14.49	414.00	438.64	674.76	288.22
Net Margin (%)	12.94	11.23	27.16	11.86	14.79
RoE (%)	13.27	8.38	25.02	9.03	29.77
Price to Earnings	9.76	75.70	71.03	--	89.29
Price-To-Book	1.21	6.15	16.79	3.72	19.17

Income Statement (₹ Cr)

	Par Drugs	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Operating Revenue	108.89	3,564.00	1,592.52	9,205.28	1,935.80
Total Income	111.99	3,686.00	1,615.23	9,449.59	1,948.58
Total Expenditure	88.94	2,792.00	969.32	8,195.15	1,485.56
EBITDA	19.95	772.00	623.20	1,010.13	450.24
Depreciation	3.76	226.00	41.96	857.51	50.83
EBIT	16.19	546.00	581.24	152.62	399.41
Interest	0.13	217.00	4.21	342.73	40.84
Other Income	3.10	122.00	22.71	244.31	12.78
Exceptional Items	0.00	12.00	0.00	-216.88	0.00
Profit before Tax	19.16	463.00	599.74	-162.68	371.35
Provision for Tax	4.66	49.00	161.10	209.13	83.14
Profit after Tax	14.49	414.00	438.64	-371.81	288.22

	Par Drugs	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Shareholder's Funds	111.99	4,940.00	1,857.45	8,142.24	1,288.82
Minority Interest	0.00	-5.00	0.51	0.00	0.00
Non-Current Liabilities	3.48	1,712.00	47.15	5,213.99	202.03
Current Liabilities	13.74	1,622.00	253.37	5,158.51	835.87
Total Liabilities	129.21	8,578.00	1,983.96	17,723.32	2,326.71

	Par Drugs	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Non-Current Assets	64.29	5,343.00	1,132.12	10,687.30	519.60
Current Assets	64.33	2,606.00	1,012.00	7,253.65	1,681.81
Total Assets	129.21	8,578.00	1,983.96	17,723.32	2,326.71
Total Debt*	0.00	2,125.00	26.49	5,495.48	259.37
Net Current Assets	50.58	984.00	758.64	2,095.14	845.94
Contingent Liabilities	0.10	768.26	17.25	95.72	19.09

	Par Drugs	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Cash From Operating Activities	16.43	390.00	292.17	1,652.60	205.05
Cash Flow from Investing Activities	-2.17	-241.00	-265.94	-826.03	-409.72
Cash from Financing Activities	--	-54.00	4.10	-38.98	283.07
Net Cash Inflow / Outflow	14.27	95.00	30.33	787.59	78.39

	Par Drugs	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
ROCE (%)	16.52	6.79	32.42	1.24	29.22
ROE (%)	13.27	8.38	25.02	-3.83	29.77
ROA (%)	11.66	4.94	22.40	-2.14	24.77
EBIT Margin (%)	14.87	15.32	36.50	1.66	20.63
Net Margin (%)	12.94	11.23	27.16	-3.93	14.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Par Drugs	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Revenue Growth (%)	4.29	18.37	45.18	0.78	46.65
EBIT Growth (%)	6.63	252.26	115.51	-70.53	62.13
Net Profit Growth (%)	2.40	377.85	95.80	-1,383.43	89.49
EPS Growth (%)	2.40	1,001.33	63.29	-484.84	78.60
Book Value Growth (%)	13.14	13.47	26.03	0.33	144.31

	Par Drugs	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Price / Earnings	9.30	76.86	70.74	-84.44	85.67
Price / Book Value	1.15	6.08	18.00	3.30	18.68
Dividend Yield (%)	0.00	0.00	0.07	0.00	0.10
EV/EBITDA	4.66	41.57	49.53	30.25	55.51
Market Cap (₹ Cr)	96.69	19,071.62	20,944.75	18,108.89	12,753.19

	Par Drugs	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debt to Equity	0.00	0.31	0.02	0.55	0.11
Short term debt to equity ratio	--	0.09	0.00	0.09	0.05
Current Ratio	4.68	1.61	3.99	1.41	2.01
Quick Ratio	4.29	1.06	2.89	0.77	1.14
Interest Coverage	146.11	3.13	143.52	0.53	10.09

	Par Drugs	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debtors to sales (%)	11.05	16.50	22.50	24.48	26.28
Asset Turnover	0.88	0.43	0.81	0.53	1.66
Receivable days	45.11	58.75	88.98	78.20	40.13
Inventory Days	18.02	75.82	56.04	93.30	60.29
Payable days	80.33	186.21	99.95	226.14	232.47
Cash Conversion Cycle	-17.20	-51.64	45.07	-54.64	-132.04

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.